Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Study Director
CONTACT
Lead
BeOne Medicines
A solid tumor is an abnormal lump or mass of tissue that forms when cells grow out of control. Solid tumors can develop in organs, bones, or soft tissues. An advanced or metastatic solid tumor is a cancer that has either grown into nearby tissues (" advanced") or spread to distant parts of the body (" metastatic"). The purpose of this study is to test whether BG-92505 is safe as monotherapy or in combination with other anti-cancer agents and if it can help to treat adults with advanced or metastatic solid tumors. BG-92505 is a pill taken by mouth. It helps turn on a protein called Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 helps break down another protein called nuclear factor erythroid 2-related factor 2 (NRF2). When NRF2 stays too active, it can help cancer cells survive, grow, and resist treatment. By working on the KEAP1-NRF2 pathway, BG-92505 may help slow or stop cancer cell growth. This study will have a dose escalation and safety expansion part. During the dose escalation part, the study doctors will test different doses of BG-92505 either alone or in combination with other anti-cancer agents to find the recommended dose that people can take without having serious side effects. During the safety expansion part, the study doctors will test the study drug in a larger number of people using 2-3 doses identified from the dose escalation part. The study will enroll participants at multiple centers worldwide who have been diagnosed with an advanced solid tumor. The overall time to participate in this study is approximately 24 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests and imaging.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
